KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Cash from Financing Activities (2018 - 2025)

Historic Cash from Financing Activities for Aurinia Pharmaceuticals (AUPH) over the last 8 years, with Q3 2025 value amounting to -$10.5 million.

  • Aurinia Pharmaceuticals' Cash from Financing Activities fell 28537.84% to -$10.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$127.3 million, marking a year-over-year decrease of 30245.07%. This contributed to the annual value of -$49.1 million for FY2024, which is 85695.91% down from last year.
  • Aurinia Pharmaceuticals' Cash from Financing Activities amounted to -$10.5 million in Q3 2025, which was down 28537.84% from -$44.4 million recorded in Q2 2025.
  • Aurinia Pharmaceuticals' Cash from Financing Activities' 5-year high stood at $205.7 million during Q4 2021, with a 5-year trough of -$49.3 million in Q1 2025.
  • Over the past 5 years, Aurinia Pharmaceuticals' median Cash from Financing Activities value was -$963500.0 (recorded in 2022), while the average stood at $3.6 million.
  • In the last 5 years, Aurinia Pharmaceuticals' Cash from Financing Activities skyrocketed by 30469.14% in 2023 and then crashed by 101830.38% in 2024.
  • Quarter analysis of 5 years shows Aurinia Pharmaceuticals' Cash from Financing Activities stood at $205.7 million in 2021, then tumbled by 99.67% to $688000.0 in 2022, then tumbled by 910.61% to -$5.6 million in 2023, then crashed by 313.23% to -$23.0 million in 2024, then surged by 54.48% to -$10.5 million in 2025.
  • Its last three reported values are -$10.5 million in Q3 2025, -$44.4 million for Q2 2025, and -$49.3 million during Q1 2025.